WALD

Waldencast plc

• Benzinga·03/19 13:42

  Waldencast's Obagi Medical Announces Collaboration With ProMD Health As Part Of Obagi's Hyaluronic Acid Program

• TipRanks·03/19 12:30

  Obagi Medical, ProMD collaborate for ALOHA program

• Reuters·03/19 12:29

  Obagi Medical partners with ProMD Health in ALOHA Program to evaluate saypha MagIQ

• Reuters·03/18 16:13

  Waldencast plc files initial beneficial ownership statement for CEO Michel Brousset

• Reuters·03/18 15:26

  Waldencast plc files Form 3 initial beneficial ownership statement for director and 10% owner Cristiano Souza

• Reuters·03/18 15:24

  Waldencast plc director Roberto Thompson Motta files initial beneficial ownership statement

• Reuters·03/18 14:34

  Waldencast plc director Aaron Chatterley files initial beneficial ownership statement

• Reuters·03/18 14:32

  Waldencast plc CFO Manuel Manfredi files initial beneficial ownership statement

• Reuters·03/18 14:28

  Waldencast plc files Form 3 initial beneficial ownership statement for Chief Growth Officer Hind Sebti

• Reuters·03/18 14:26

  Waldencast plc Director Brookie Kelly files initial beneficial ownership statement

• TipRanks·03/17 11:16

  Waldencast price target lowered to $2.50 from $3.50 at Alliance Global

• Dow Jones·03/16 19:13

  Waldencast Price Target Cut to $2.00/Share From $3.00 by Telsey Advisory Group

• Dow Jones·03/16 19:13

  Waldencast Is Maintained at Market Perform by Telsey Advisory Group

• Benzinga·03/16 19:03

  Telsey Advisory Group Maintains Market Perform on Waldencast, Lowers Price Target to $2

• Dow Jones·03/16 16:27

  Waldencast Is Maintained at Buy by Canaccord Genuity